Nov 16, 2023

Mabwell Announces the Appointment of Dr. Hai Wu as the President of R&D

➞

Oct 30, 2023

Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market

➞

Oct 25, 2023

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO

➞

Oct 23, 2023

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

➞

Sep 27, 2023

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

➞

Sep 26, 2023

Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador

➞

Sep 22, 2023

FDA Grants Fast Track Designation to 9MW3011

➞

Sep 06, 2023

Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics

➞

Sep 05, 2023

Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs

➞

Aug 28, 2023

Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines

➞